FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Parathyroid Hormone Injection
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Takeda Pharmaceuticals USA Inc. (Revised 01/09/2026)

Company Contact Information:
866-888-0660

Presentation	Posting Date	Related Information
Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)	01/09/2026	Discontinuation of the manufacture of the drug Dear Patient Letter: NATPARA® (PARATHYROID HORMONE) U.S. SPECIAL USE PROGRAM CLOSES DECEMBER 31, 2025
Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)	01/09/2026	Discontinuation of the manufacture of the drug Dear Patient Letter: NATPARA® (PARATHYROID HORMONE) U.S. SPECIAL USE PROGRAM CLOSES DECEMBER 31, 2025
Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)	01/09/2026	Discontinuation of the manufacture of the drug Dear Patient Letter: NATPARA® (PARATHYROID HORMONE) U.S. SPECIAL USE PROGRAM CLOSES DECEMBER 31, 2025
Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)	01/09/2026	Discontinuation of the manufacture of the drug